Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

ATLANTA, May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. ALIM (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the 20^th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019.

Mr. Eiswirth's presentation will be held at 2:00 PM PT in Room 9 of the Beverly Hilton Hotel, 9876 Wilshire Blvd. in Beverly Hills, Calif.  Investors interested in one-on-one meetings should contact the conference organizers at conference@brileyfbr.com. 

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.